Chair and Chief Executive, Puma Biotechnology Inc.

Auerbach established Puma Biotechnology in 2010 with a focus on developing cancer treatment pharmaceuticals for commercial use. He previously founded and ran Cougar Biotechnology Inc., which he sold in 2009 to Johnson & Johnson for about $1 billion. Puma in-licensed Alisertib from Takeda in September. Alisertib has been tested in clinical trials in patients with metastatic cancers including breast cancer, small-cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma and acute myeloid leukemia. Under the terms of the agreement, Puma will assume sole responsibility for the global development and commercialization of the treatment. 

YEARS ON THE LA500: 8